The Phase I trial of the combination therapy saw a an approximate 66% rate of near-complete remission in its cohort of breast ...

As more companies are investigating radiopharmaceuticals, the complexities and red tape faced by sponsors are becoming more ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

As the first cohort of patients are dosed in the Phase II trial, multiple new trial sites are added for the glioblastoma ...

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

JELMYTO (mitomycin) for pyelocalyceal solution treats low-grade, upper tract urothelial cancer in adult population. Credit: SewCreamStudio/Shutterstock. UroGen Pharma ...

Sequana Medical’s other lead candidate is alfapump, a device for patients with a buildup of fluid in the abdomen. Image credit: Shutterstock / Sadovnikova Olga. Following positive data reported ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as ...

Anocca has submitted its first clinical trial application (CTA) for conducting the Phase I/II VIDAR-1 trial to the EMA.